AI Engines For more Details: Perplexity Kagi Labs You
Coronary Artery Disease (CAD): Dilazep dihydrochloride is used in the management of coronary artery disease, a condition characterized by the narrowing or blockage of the coronary arteries that supply blood to the heart muscle. Dilazep acts as a coronary vasodilator, meaning it dilates the coronary arteries, which improves blood flow to the heart muscle and reduces myocardial ischemia (lack of oxygen).
Angina Pectoris: Angina pectoris is chest pain or discomfort caused by reduced blood flow to the heart muscle. Dilazep dihydrochloride can help alleviate angina symptoms by dilating the coronary arteries, improving blood flow, and reducing the workload on the heart. It is often used as an adjunctive therapy in individuals with stable angina who are not adequately controlled with other medications such as beta-blockers or calcium channel blockers.
Peripheral Arterial Disease (PAD): Dilazep dihydrochloride may also be used in the treatment of peripheral arterial disease, a condition characterized by narrowed or blocked arteries in the legs, arms, or other parts of the body. By dilating the peripheral arteries, dilazep improves blood flow to the affected limbs, reducing symptoms such as leg pain or cramping during physical activity (intermittent claudication).
Antiplatelet Effect: In addition to its vasodilator effects, dilazep dihydrochloride also has antiplatelet properties, meaning it inhibits the aggregation of platelets, which are blood cells involved in clot formation. This antiplatelet effect helps reduce the risk of thrombosis (blood clot formation) in the coronary and peripheral arteries, which can lead to myocardial infarction (heart attack) or ischemic stroke.
Side Effects: Common side effects of dilazep dihydrochloride may include headache, dizziness, flushing, palpitations, and gastrointestinal symptoms such as nausea or abdominal discomfort. These side effects are usually mild and transient and may diminish with continued use or dosage adjustments. However, more serious side effects, such as hypotension (low blood pressure), bradycardia (slow heart rate), or allergic reactions, may occur rarely and require medical attention.
Contraindications: Dilazep dihydrochloride is contraindicated in individuals with known hypersensitivity or allergy to the medication or any of its components. It should be used with caution in individuals with hypotension, bradycardia, heart block, or severe hepatic impairment.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 0.9 | 0.9 | |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.9 | 0.9 | |
| Allergies | 0.4 | 0.4 | |
| Allergy to milk products | 0.4 | 0.5 | -0.25 |
| Alopecia (Hair Loss) | 0.8 | 0.8 | |
| Alzheimer's disease | 1.1 | 1.3 | -0.18 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | 0 |
| Ankylosing spondylitis | 1.6 | 0.3 | 4.33 |
| Anorexia Nervosa | 0.4 | 0.3 | 0.33 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.3 | 1.33 |
| Asthma | 0.1 | -0.1 | |
| Atrial fibrillation | 1 | 0.9 | 0.11 |
| Autism | 1.2 | 1.8 | -0.5 |
| Barrett esophagus cancer | 0.4 | -0.4 | |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 0.9 | 0.9 | |
| Brain Trauma | 0.1 | -0.1 | |
| Cancer (General) | 0.6 | -0.6 | |
| Carcinoma | 1.3 | 0.5 | 1.6 |
| Celiac Disease | 0.8 | 0.8 | 0 |
| Cerebral Palsy | 0.4 | 0.1 | 3 |
| Chronic Fatigue Syndrome | 1.6 | 2.9 | -0.81 |
| Chronic Kidney Disease | 0.9 | 0.3 | 2 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 1.1 | |
| Chronic Urticaria (Hives) | 0.8 | 0.1 | 7 |
| Coagulation / Micro clot triggering bacteria | 1.2 | 0.4 | 2 |
| Colorectal Cancer | 1.8 | 0.2 | 8 |
| Constipation | 0.3 | 0.3 | |
| Coronary artery disease | 0.4 | 0.4 | |
| COVID-19 | 2.3 | 2 | 0.15 |
| Crohn's Disease | 1.7 | 0.9 | 0.89 |
| cystic fibrosis | 0.5 | 0.1 | 4 |
| deep vein thrombosis | 0.5 | 0.4 | 0.25 |
| Depression | 2.7 | 2.8 | -0.04 |
| Dermatomyositis | 0.4 | 0.4 | |
| Eczema | 0.4 | 1.2 | -2 |
| Endometriosis | 1.3 | 1.3 | |
| Epilepsy | 0.8 | 1.2 | -0.5 |
| Fibromyalgia | 1.1 | 0.2 | 4.5 |
| Functional constipation / chronic idiopathic constipation | 1.3 | 0.2 | 5.5 |
| gallstone disease (gsd) | 0.5 | 0.5 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.4 | -3 |
| Generalized anxiety disorder | 0.7 | 0.1 | 6 |
| Glioblastoma | 0.4 | -0.4 | |
| Graves' disease | 0.5 | 0.5 | |
| Halitosis | 0.1 | 0.4 | -3 |
| Hashimoto's thyroiditis | 0.1 | 0.4 | -3 |
| Hidradenitis Suppurativa | 0.7 | 0.7 | |
| High Histamine/low DAO | 0.3 | 0.3 | |
| hyperglycemia | 0.2 | 0.5 | -1.5 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1 | 0.9 | 0.11 |
| Hypoxia | 0.5 | 0.5 | |
| IgA nephropathy (IgAN) | 0.5 | -0.5 | |
| Inflammatory Bowel Disease | 2 | 1.5 | 0.33 |
| Insomnia | 0.5 | 0.1 | 4 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.5 | 0.5 | |
| Irritable Bowel Syndrome | 0.6 | 0.8 | -0.33 |
| Liver Cirrhosis | 1.3 | 0.8 | 0.63 |
| Long COVID | 1.4 | 1 | 0.4 |
| Lung Cancer | 0.2 | 0.2 | |
| Mast Cell Issues / mastitis | 0.5 | 0.5 | |
| ME/CFS with IBS | 0.4 | 0.1 | 3 |
| ME/CFS without IBS | 0.6 | 0.9 | -0.5 |
| Menopause | 0.2 | 0.2 | |
| Metabolic Syndrome | 2 | 1.4 | 0.43 |
| Mood Disorders | 3 | 2.8 | 0.07 |
| multiple chemical sensitivity [MCS] | 1.1 | 1.1 | |
| Multiple Sclerosis | 1.8 | 2.1 | -0.17 |
| neuropathic pain | 0.1 | -0.1 | |
| Neuropathy (all types) | 0.4 | 0.2 | 1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | 0.4 | 0.25 |
| NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
| Obesity | 1.5 | 1.8 | -0.2 |
| obsessive-compulsive disorder | 1.8 | 0.5 | 2.6 |
| Osteoarthritis | 0.8 | 0.8 | |
| Osteoporosis | 0.3 | 0.1 | 2 |
| pancreatic cancer | 0.4 | 0.4 | |
| Parkinson's Disease | 2.5 | 0.8 | 2.13 |
| Polycystic ovary syndrome | 0.6 | 0.6 | |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.1 | -0.1 | |
| Psoriasis | 0.8 | 1.3 | -0.63 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 0.2 | 6.5 |
| Schizophrenia | 0.9 | 0.9 | |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.9 | 0.8 | 0.13 |
| Sleep Apnea | 0.1 | -0.1 | |
| Slow gastric motility / Gastroparesis | 0.4 | 0.4 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.7 | |
| Stress / posttraumatic stress disorder | 0.8 | 0.1 | 7 |
| Systemic Lupus Erythematosus | 1.6 | 1.6 | |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 0.9 | 0.4 | 1.25 |
| Type 2 Diabetes | 2 | 1.4 | 0.43 |
| Ulcerative colitis | 1.2 | 1.1 | 0.09 |
| Unhealthy Ageing | 1.1 | 0.3 | 2.67 |
| Vitiligo | 0.5 | 0.4 | 0.25 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.80.143 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.80.143 ]
